HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Albanese, A. Articles by Filippini, G. Search for Related Content PubMed Articles by Albanese, A. Articles by Filippini, G.

Gabapentin improved sensory and motor symptoms in the restless legs syndrome

Key Words: restless legs syndrome • excitatory amino acid antagonists • acetic acids

The first 150 words of the full text of this article appear below.

Design
13 week randomised (allocation concealed^*), blinded (clinicians and patients),^* placebo controlled, crossover trial.

Setting
Madrid, Spain.

Patients
24 patients who were 33–75 years of age (mean age 55 y, 67% women) and were diagnosed with idiopathic RLS (established by the International RLS Study Group). Patients with ferritin concentrations <20 µg/ml were excluded. 21 patients (88%) completed the study.

Intervention
Patients were allocated to sequence 1 (gabapentin followed by placebo) or sequence 2 (placebo followed by gabapentin). Gabapentin was given at an initial dose of 600 mg/day, up to a maximum dose of 2400 mg/day. The sequences lasted 6 weeks with a 1 week washout period, and then patients crossed over to the alternate sequence.

Main outcome measures
Difference between groups for change from baseline to week 6 on the RLS Rating Scale (RLS symptom severity classified as mild [0–15 points], moderate [16–25 points], or severe [26–40 points]). Secondary outcome measures included patient global impression of . . . [Full text of this article]

Alberto Albanese, MD, Graziella Filippini, MD

Istituto Nazionale Neurologico Carlo Besta
Milan, Italy